A Bayesian Dose-Individualization Method for Warfarin
暂无分享,去创建一个
[1] M. Meyer,et al. Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? , 2012, Journal of clinical pharmacy and therapeutics.
[2] N. Holford,et al. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. , 2004, British journal of clinical pharmacology.
[3] W. Ageno,et al. A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy , 2000, Thrombosis and Haemostasis.
[4] M. Daschbach,et al. Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. , 1987, Journal of general internal medicine.
[5] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[6] J. Deely,et al. A sequential Bayesian algorithm for dose individualisation of carboplatin , 1997, Cancer Chemotherapy and Pharmacology.
[7] R. Pendleton,et al. Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study , 2010, Therapeutic drug monitoring.
[8] A. Forster,et al. Effect of Study Setting on Anticoagulation Control * , 2006 .
[9] R. Kravitz,et al. From Insight to Implementation: Lessons from a Multi-site Trial of a PDA-based Warfarin Dose Calculator , 2005 .
[10] T. Theofanous,et al. Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. , 1973, Journal of pharmaceutical sciences.
[11] A. Forster,et al. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis , 2007, Canadian Medical Association Journal.
[12] A. Forster,et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis , 2008, Canadian Medical Association Journal.
[13] Y. Caraco,et al. CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.
[14] Susan Regan,et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.
[15] David C. Anderson,et al. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1996, Archives of internal medicine.
[16] C. Staatz,et al. Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Area Under the Concentration-Time Curve: Is This Clinically Useful for Dosage Prediction Yet? , 2011, Clinical pharmacokinetics.
[17] B. Eliasson,et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. , 2012, Thrombosis research.
[18] Stephen B. Duffull,et al. Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation , 2011, Pharmaceutical Research.
[19] M. Bhavnani,et al. A WARFARIN INDUCTION REGIMEN FOR OUT‐PATIENT ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION , 1998, British journal of haematology.
[20] H. Echizen,et al. CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences , 2004, Clinical pharmacology and therapeutics.
[21] Lewis B. Sheiner,et al. Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[22] C. Kirkpatrick,et al. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. , 2003, British journal of clinical pharmacology.
[23] P. J. Ryan,et al. Computer control of anticoagulant dose for therapeutic management. , 1989, BMJ.
[24] L B Sheiner,et al. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.
[25] Anticoagulants in the Secondary Prevention of Events in Coronary Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction , 1994, The Lancet.
[26] D. Mungall,et al. Outpatient management of warfarin therapy: comparison of computer-predicted dosage adjustment to skilled professional care. , 1991, Therapeutic drug monitoring.
[28] P J Huber,et al. A Bayesian feedback method of aminoglycoside dosing , 1985, Clinical pharmacology and therapeutics.
[29] D. Pennell,et al. Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.
[30] A. Forster,et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. , 2006, Chest.
[31] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[32] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[33] A. Boddy,et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. , 1995, European journal of cancer.
[34] G. Raskob,et al. Predicting the Daily Prothrombin Time Response to Warfarin , 1990, Therapeutic drug monitoring.
[35] M G Amato,et al. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. , 1998, Archives of internal medicine.
[36] J. Schellens,et al. Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[37] N H Holford,et al. The Target Concentration Approach to Clinical Drug Development , 1995, Clinical pharmacokinetics.
[38] N. Holford. Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.
[39] D. Mungall,et al. The use of a Bayesian forecasting model in the management of warfarin therapy after total hip arthroplasty. , 1999, The Journal of arthroplasty.
[40] John Anderson. Computer assisted management of warfarin treatment , 1984 .
[41] L. Aarons,et al. A Bayesian Method Based on Clotting Factor Activity for the Prediction of Maintenance Warfarin Dosage Regimens , 2003, Therapeutic Drug Monitoring.
[42] Peter Wood,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.
[43] J. Jespersen,et al. Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.
[44] D. P. Bentley,et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. , 1984, British medical journal.
[45] N H Holford,et al. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. , 1986, Clinical pharmacokinetics.
[46] P. Deloukas,et al. A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age , 2010, Clinical pharmacology and therapeutics.
[47] P. Lavori,et al. Effect of home testing of international normalized ratio on clinical events. , 2010, The New England journal of medicine.
[48] D. Mungall,et al. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. , 1985, Therapeutic drug monitoring.
[49] K. Hampton,et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. , 2000, Age and ageing.
[50] Panos Deloukas,et al. The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.
[51] Thomas M. Ludden,et al. Evaluation of a Bayesian Regression Program for Predicting Warfarin Response , 1989, Therapeutic drug monitoring.
[52] D. Witt,et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. , 2005, Chest.
[53] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.
[54] M. Moia,et al. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). , 2001, Haematologica.
[55] R L Berg,et al. Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing , 2010, Clinical pharmacology and therapeutics.
[56] M. Leaning,et al. Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy. , 1999, British journal of clinical pharmacology.
[57] Janice D Nunnelee,et al. Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64. , 2009, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.